drugset / Trial / NCT01351168

Use of Zolpidem in Parkinson's Disease

NCT01351168

Phase 2 Withdrawn Rush University Medical Center
RandomizedCrossoverQuadruple-blindTreatment

Summary

Levodopa treatment is associated with long-term complications. Dopamine deficiency is associated with abnormal activity in certain parts of the brain. Zolpidem may change this abnormal activity and, by doing so, may work in a different way than levodopa to help parkinsonism. The working hypothesis for this aim is that ZLP is superior to placebo in acutely improving motor symptoms of PD. The investigators will conduct a randomized,controlled, double-blind, cross-over study in 40 patients with PD. Each patient will receive placebo, levodopa and 2 doses of ZLP in a randomized order on 4 different occasions, about one week apart.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Levodopa Small molecule 200 mg Oral
Subject Zolpidem Small molecule 7.5 mg Oral
Subject Zolpidem Small molecule 10 mg Oral
Subject Zolpidem Small molecule 15 mg Oral

Indications